<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681690</url>
  </required_header>
  <id_info>
    <org_study_id>G-NeSS</org_study_id>
    <nct_id>NCT04681690</nct_id>
  </id_info>
  <brief_title>German National Registry for NSS</brief_title>
  <official_title>German National Registry for Nephron-Sparing Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association of Urologic Oncology (AUO)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association of Urologic Oncology (AUO)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The G-NeSS Registry prospectively collects data on clinical and outcome variables from&#xD;
      patients undergoing partial nephrectomy for renal masses. Analyses of data aims at&#xD;
      identifying key factors determining the quality of surgical care in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Today the majority of patients with renal tumors is diagnosed with localized disease amenable&#xD;
      to nephron-sparing surgery (NSS). Partial nephrectomy (PN) constitutes the reference standard&#xD;
      treatment for small renal masses according to international guidelines. Open PN ist still the&#xD;
      predominant apporach in Germany, but the use of minimally-invasive surgery has continously&#xD;
      increased over the last decades. Specifically, robotic surgery is on the rise and may&#xD;
      facilitate the adoption of a minimally-invasive PN approach even in more complex renal&#xD;
      tumours. Real world data on the outcomes of PN according to the surgical approach are&#xD;
      limited. Data from cancer registries and health insurance databases usually lack important&#xD;
      information an key patient und tumour characteristics, such as tumour complexity.&#xD;
&#xD;
      The G-NESS registry database aims at prospectively collecting such clinical and outcome data&#xD;
      from patients undergoing PN. Data collection includes perioperative variables on patient&#xD;
      characteristics, tumour location and complexity, surgical approach, intra-/postoperative&#xD;
      complications, and kidney function. Follow-up based on questionnaires is conducted after&#xD;
      predefined intervals (i.e. 30 days, 12 months, 24 months, and 60 months) in order to receive&#xD;
      information on long-term kidney function, comorbidities, and survival. The information&#xD;
      received from the database can help to better define the optimal surgical care for patients&#xD;
      with renal masses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>60 Months</target_duration>
  <primary_outcome>
    <measure>Complication rate</measure>
    <time_frame>60 months</time_frame>
    <description>Complication rate according to Clavien-Dindo in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative glomerular inflitration rate</measure>
    <time_frame>60 months</time_frame>
    <description>Rate in ml/min.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>60 months</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Kidney Neoplasm</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention, observation only.</intervention_name>
    <description>Observation only</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a renal mass eligible for partial nephrectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Localized renal parenchymal mass amenable to nephron-sparing surgery&#xD;
&#xD;
          -  Adequate imaging of the abdomen (CT or MR with contrast)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with (or suspected to have) urothelial cancer of the kidney&#xD;
&#xD;
          -  Prior nephron-sparing surgery on ipsilateral kidney&#xD;
&#xD;
          -  metastasized renal cell carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Harke, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>MHH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Siemer, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Saarland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Weikert, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Vivantes Humboldt-Klinikum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Harke, Dr.</last_name>
    <phone>0511/532</phone>
    <phone_ext>36 47</phone_ext>
    <email>harke.nina@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidrun Rexer</last_name>
    <phone>039827/79 677</phone>
    <email>GNeSS@MeckEvidence.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MHH</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Nina Harke, Dr.</last_name>
      <phone>0511/532-</phone>
      <phone_ext>36 47</phone_ext>
      <email>harke.nina@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Nina Harke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Humboldt Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Steffen Weikert, Prof. Dr.</last_name>
      <phone>030/130 12-12 91</phone>
      <email>Steffen.Weikert@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Weikert, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Siemer, Prof. Dr.</last_name>
      <phone>+49-(0)6841-1624702</phone>
      <email>stefan.siemer@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Stefan Siemer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

